Synthesis, Structure, and Photophysical Properties of Platinum Compounds with Thiophene-Derived Cyclohexyl Diimine Ligands.

Platinum(II) and platinum(IV) compounds were prepared by the stereoselective and regioselective reactions of thiophene-derived cyclohexyl diimine C^N^N-ligands with [Pt2Me4(µ-SMe2)2]. Newly synthesized ligands were characterized by NMR spectroscopy and elemental analysis, and Pt(II)/Pt(IV) compounds were characterized by NMR spectroscopy, elemental analysis, high-resolution mass spectrometry, and single-crystal X-ray diffraction. UV-vis absorbance and photoluminescence measurements were performed on newly synthesized complexes, as well as structurally related Pt(II)/Pt(IV) compounds with benzene-derived cyclohexyl diimine ligands, in dichloromethane solution, as solids, and as 5% by weight PMMA-doped films. DFT and TD-DFT calculations were performed, and the results were compared with the observed spectroscopic properties of the newly synthesized complexes. X-ray total scattering measurements and real space pair distribution function analysis were performed on the synthesized complexes to examine the local- and intermediate-range atomic structures of the emissive solid states.

Photophysical Properties of Cyclometalated Platinum(II) Diphosphine Compounds in the Solid State and in PMMA Films.

Platinum(II) compounds were synthesized with both chelate cyclometalated ligands and chelate diphosphine ligands. The cyclometalated ligands include phenylpyridine and a benzothiophene-containing ligand. The three new benzothiophene compounds were characterized by nuclear magnetic resonance (NMR) spectroscopy, high-resolution mass spectrometry (HR-MS), and photophysical measurements. In the case of one compound, L1-DPPM, the structure was determined by single crystal X-ray diffraction. The structural coherence of the noncrystalline emissive solid state was measured by X-ray total scattering real space pair distribution function analysis. Quantum yield values of all of the platinum compounds measured in the solid state and in PMMA films were much greater than in solution.

Platinum Complexes from C-H Activation of Sterically Hindered [C

Primary amines and benzothiophene-3-carboxaldehyde were reacted to give four large, bulky imine ligands. These imine ligands were reacted with a tetramethyl platinum dimer and by heteroatom-assisted C-H activation, both monometalated compounds and bismetalated compounds were synthesized. In all cases, five-membered platinacycles were formed. The compounds were characterized by NMR spectroscopy, and one bismetalated compound was characterized by single-crystal X-ray diffraction. The UV-vis absorption and emission spectra and the excited-state lifetimes were recorded for these complexes. Density functional theory (DFT) and time-dependent-DFT calculations were performed to aid in the assignment of the absorption and emission spectra of the newly synthesized complexes.

A ruthenium-platinum metal complex that binds to sarcin ricin loop RNA and lowers mRNA expression.

IT127 is a dinuclear transition metal complex that contains a Pt(ii) and a Ru(iii) metal center. We have shown that IT127 is significantly more effective in binding the 29-base sarcin ricin loop (SRL) RNA in comparison to Cisplatin, a hallmark anticancer agent. Binding site analysis shows that IT127 prefers purine bases and the GAGA tetraloop region of SRL RNA. Our results with a dihydrofolate reductase (DHFR) model system reveal that IT127 binding to mRNA reduces translation of DHFR enzyme and that the Ru(iii) and Pt(ii) centers in IT127 appear to work in a synergistic manner.

Synthesis and characterization of water-soluble, heteronuclear ruthenium(III)/ferrocene complexes and their interactions with biomolecules.

The reaction of Na[RuCl4(SO(CH3)2)2], 1, with one equivalent of FcCONHCH2C6H4N (Fc=FeC10H9), L1, FcCOOCH2CH2C3H3N2, L2, FcCOOC6H4N, L3, afforded the dinuclear species, Na[FcCONHCH2C6H4N[RuCl4(SO(CH3)2)]], RuL1, Na[FcCOOCH2CH2C3H3N2[RuCl4(SO(CH3)2)]], RuL2, Na[FcCOOC6H4N(RuCl4(SO(CH3)2))], RuL3, respectively, yielding, in each case, a ferrocene moiety bridged to a ruthenium center. The complexes were characterized by NMR, IR, and XRD (X-ray diffraction). The sulfoxide ligands are bonded to the metal through the sulfur atom. The complexes were evaluated for their biological activity with pBluescript DNA plasmid, and the protein BSA (bovine serum albumin). These reactions were monitored by XAS (X-ray absorption spectroscopy), EXAFS (extended X-ray Absorption Fine Structure), NMR, UV/visible, emission spectroscopy, and gel electrophoresis. Donor atoms from the biomolecules substitute for the chloride ligands in the parent complexes.

RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.

AH197, a trinuclear Ru(III)/Pt(II) metal complex, is strikingly more effective than the hallmark anticancer drug cisplatin and the Ru(III) clinical candidate NAMI-A in its binding to RNA and inhibition of primer DNA synthesis. Heteromultinuclear complexes could potentially serve as far better chemotherapeutics than mononuclear complexes.

Hetero-multinuclear ruthenium(III)/platinum(II) complexes that potentially exhibit both antimetastatic and antineoplastic properties.

Hetero-multinuclear, platinum/ruthenium species were synthesized and tested for their effect on the motility of A549 (nonsmall cell lung) and MDA-MB-231 (breast) cancer cells and for their ability to inhibit DNA mobility using gel electrophoresis. It was found that the Ru(2)Pt trinuclear species [Na(2)]{[Ru(III)Cl(4)(DMSO-S)(-µ-pyz)](2)Pt(II)Cl(2)}, AH197, was much more efficient at inhibiting cell motility than [C(3)N(2)H(5)][Ru(III)Cl(4)(DMSO-S)(C(3)N(2)H(4))], NAMI-A, while the dinuclear RuPt species [K][Ru(III)Cl(4)(DMSO-S)(-µ-pyz)Pt(II)(DMSO-S)Cl(2)], IT127, was slightly better than NAMI-A. However, the dinuclear species retarded the electrophoretic mobility of DNA greater than both the trinuclear complex and cisplatin. The metal complexes and their respective BSA protein/metal adducts were studied by X-ray absorption spectroscopy. The spectra led to the conclusion that BSA donor atoms have substituted for the chloride ligands and perhaps the DMSO ligands.

Poly[µ(3)-chlorido-µ(2)-chloridodichlorido(µ-dimethyl sulfoxide-κO:S)(dimethyl sulfoxide-κO)(µ-pyrimidine-κN:N')-ruthenium(III)sodium].

The title complex, [NaRuCl(4)(C(4)H(4)N(2))(C(2)H(6)OS)(2)](n), is the sodium salt of monoanionic octa-hedral [Ru(III)Cl(4)(pyrimidine)(DMSO)](-) in which the sulfur-bound dimethyl sulfoxide (DMSO) and pyrimidine ligand are oriented trans to one another on the Ru(III) atom. The average of the four Ru-Cl bond lengths is 2.355 (15) Å, and the Ru-S and Ru-N bond lengths are 2.2853 (3) and 2.1165 (11) Å, respectively. The complex forms a chain, with a six-coordinate sodium ion bridging the ruthenium(III) units. The sodium cation is coordinated by cis-chloride ligands on ruthenium [Na-Cl = 2.9576 (7) and 2.6988 (7) Å], chloride and DMSO ligands from the ruthenium complexes related by inversion [Na-Cl and Na-O = 2.8888 (7) and 2.2623 (12) Å, respectively], a nitro-gen ligand from the pyrimidine of the tetrachlorido-ruthenium(III) complex related by the twofold rotation axis [Na-N = 2.5224 (14) Å] and an oxygen-bound DMSO [Na-O = 2.3165 (12) Å].

Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.

A new type of mixed-metal trinuclear complex containing platinum(II) and ruthenium(III) fragments that resemble both cisplatin and NAMI-A has been synthesized and characterized by IR, 1H NMR, elemental analysis, and X-ray crystallography. The water-soluble compound Na2{trans,cis,trans-[RuIIICl4(DMSO-S)(mu-pyz)]2PtIICl2} (AH-197, pyz = pyrazine) was assessed for its effects on DNA mobility and toxicity against human cancer cell lines. When compared to cisplatin and KP-1019 (which structurally resembles NAMI-A), IC50 results showed that AH-197 had an intermediate toxicity. When this data was coupled with a subsequent COMPARE evaluation (standard COMPARE queries resulted in insignificant correlation coefficients (<0.70) while very low COMPARE correlation coefficients were found in the matrix queries as well), AH-197 yielded a correlation coefficient of 0.19 when compared to cisplatin and 0.25 when compared to KP1019 indicating that AH-197 has a unique behavior.